Ascending Single Dose Study of the Safety, Tolerability and Pharmacokinetics of NSA-789 Administered Orally to Healthy Japanese Male Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2009
At a glance
- Drugs NSA 789 (Primary)
- Indications Dementia
- Focus Adverse reactions; Pharmacokinetics
- 28 Jan 2009 Status changed from planning to completed as reported by ClinicalTrials.gov.
- 03 Mar 2008 New trial record.